News - TRIM-edicine

Feb 20 2019

Dr. Ma’s group published two additional articles revealing the physiological role and potential translational application of MG53 in corneal injury as well as MG53’s role in preventing valvular heart disease.

MG53 promotes corneal wound healing and mitigates fibrotic remodeling in rodents. Link MG53 Protein Protects Aortic Valve Interstitial Cells From Membrane Injury and Fibrocalcific Remodeling. Link

Nov 30 2018

Dr. Ma was invited to present at “TEDxColumbus: On The Edge”. (video inside)

Ten years ago, Dr. Jianjie Ma and his team discovered the protein MG53. Dr. Ma now serves at the Karl P Klassen Chair at The Ohio State University and shares his continued breakthrough research on the many ways in which this magical protein can potentially cure human diseases of...

Mar 28 2015

人民网：“细胞修理工”或可预防急性肾损伤

原文链接据新华社华盛顿电（记者林小春）急性肾损伤是心脏手术及化疗等常见的危重并发症。中美科学家说，一种叫做MG53的蛋白也许能预防出现这一危及生命的医学难题，从而改变目前无药可治疗或预防急性肾损伤的局面。这项成果当天发表在美国《科学－转化医学》杂志上。负责研究的俄亥俄州立大学麻建杰教授对新华社记者说...

Mar 28 2015

人民网：“细胞修理工”或可预防急性肾损伤

Jul 26 2014

人民网：新型蛋白MG53能像“创可贴”一样即时修复“伤口”

原文链接

科技日报讯（邹争春记者陈磊）中美科研人员历经2年联合研究发现，新型蛋白MG53对感染、创伤、缺血等多种急性肺损伤具有保护作用。该蛋白能像“创可贴”一样，即时修复各种损伤对细胞膜造成的“伤口”，为临床急性肺损伤治疗提供新思路。7月18日，相关研究发表在《自然》杂志子刊《自然通讯》上。该研究由第三军医大学大坪医院野战外科研究所心血管内科曾春雨教授、陈垦博士等组成的团队和美国俄亥俄州立大学麻建杰教授团队联合完成。创伤、缺血、感染等多种严重的病理生理状态均会导致...

TRIM-edicine, Inc. was awarded a new Phase II SBIR grant (2019-2022) to advance commercialization efforts of MG53 in the wounding healing application.

Dr. Ma’s group published two additional articles revealing the physiological role and potential translational application of MG53 in corneal injury as well as MG53’s role in preventing valvular heart disease.

Dr. Ma was invited to present at “TEDxColumbus: On The Edge”. (video inside)

TRIM-edicine was awarded a Phase I SBIR grant (2017-2018) for conducting proof-of-concept studies with MG53 in wounding healing application.

TRM-edicine, Inc received a Phase II SBIR grant from NIH, for a total award of $1.8M.

New TRIM-edicine website launched!

人民网：“细胞修理工”或可预防急性肾损伤

人民网：“细胞修理工”或可预防急性肾损伤

Dr. Jianjie Ma’s group at The Ohio State University published a paper entitled “MG53–mediated cell membrane repair protects against acute kidney injury” in Science Translational Medicine. A review of the article was published in Nature Review Nephrology: Research Highlights, May 2015

人民网：新型蛋白MG53能像“创可贴”一样即时修复“伤口”

TRIM-edicine received an NIH-SBIR grant to develop pre-clinical studies with MG53.

Dr. Jianjie Ma’s group at The Ohio State University published a paper “Treatment of acute lung injury by targeting MGG53-mediated cell membrane repair” in Nature Communications

TRIM-edicine, Inc was awarded a SMARTT (Science Moving towArds Research Translation and Therapy ) grant from NHLBI for supporting of CMC development.

TRIM-edicine was awarded a SBIR I grant entitled “Targeting ATAP-mediated apoptosis in treatment of prostate cancer” by NIH-NCI.

TRIM-edicine held a Pre-IND meeting with FDA on the use of rhMG53 as therapeutics for treatment of unmet medical needs.

TRIM-edicine was awarded US patent on serum MG53 as a diagnostic marker for tissue injury.

TRIM-edicine established a new R&D facility at the TechColumbus Technology Center, Columbus, Ohio.

TRIM-edicine was awarded $1.5 M from NIH in support of a SBIR phase II project entitled “Protein Therapeutics in Muscular Dystrophy”.

TRIM-edicine publishes its findings on MG53, cell membrane repair, and muscular dystrophy on the cover page of Science Translational Medicine.